Instrument/ | ETN + MTX | DMARD + MTX | P value |
---|---|---|---|
Time on therapy | |||
HAQ Score | Mean Score (% Improvement from Baseline) (N) | ||
Baseline | 1.37 (0%) (N = 197) | 1.41 (0%) (N = 103) | |
Week 16 | 0.69 (49.4%) (N = 193) | 0.87 (38.3%) (N = 100) | 0.025* |
HAQ Proportion | Patients achieving HAQ Score ≤ 0. 5, Proportion (%) | ||
Baseline | 28/197 (14.2%) | 13/103 (12.6%) | |
Week 16 | 100/193 (51.8%) | 39/100 (39.0%) | 0.048** |
SF-36 Physical Component Summary Scores | Mean Score (% Improvement from Baseline) (N) | ||
Baseline | 30.5 (0%) (N = 193) | 30.1 (0%) (N = 100) | |
Week 16 | 40.4 (31.4%) (N = 189) | 37.3 (22.8%) (N = 96) | 0.003* |
SF-36 Mental Component Summary Scores | Mean Score (% Improvement from Baseline) (N) | ||
Baseline | 42.9 (0%) (N = 193) | 42.4 (0%) (N = 100) | |
Week 16 | 50.2 (17.5%) (N = 189) | 47.8 (13.3%) (N = 96) | 0.047* |